GHK-Cu in Australia

Copper-binding tripeptide (glycyl-L-histidyl-L-lysine:Cu²⁺). GHK-Cu is a naturally occurring tripeptide that binds copper with high affinity. It was first isolated from human plasma in 1973, where its concentration falls from roughly 200 ng/mL in young adults to about 80 ng/mL by age 60. Research interest spans wound repair, collagen synthesis, hair follicle biology and gene-expression modulation in aged tissue. The same molecule appears at low concentration in cosmetic serums; the research vial is the pure copper complex.

Collagen and elastin synthesis: fibroblast stimulation and lysyl oxidase activity. Wound healing: closure rate and remodelling in animal and human wounds. Gene expression: broad transcriptional effects in aged and cancer cell lines. Hair follicle biology: follicle size and growth-phase markers. Antioxidant defence: sOD activation and iron release inhibition. Wound studies in animals and small human trials reported faster closure and increased collagen deposition. Controlled facial studies of topical GHK-Cu creams reported improved skin thickness, elasticity and fine-line depth over 12 weeks. Hair studies show increased follicle size in culture and animal models. Most data are topical or in-vitro; injectable research is limited to preclinical work.

Twelve-week controlled facial studies reported increased skin thickness and density on ultrasound, improved elasticity and reduced wrinkle depth on profilometry; wound studies reported faster closure; follicle cultures showed increased follicle size. The human data are topical.

Topical GHK-Cu is well tolerated in the published trials, with occasional mild irritation. There are no human safety data for injectable use; copper exposure from the peptide is microgram-scale and bound.

Published GHK-Cu studies specify their own amounts and routes, and those vary by model and endpoint. Peptide Aus products are supplied for in-vitro laboratory research, so we do not provide dosing, cycle or usage guidance for people. For laboratory preparation, the reconstitution calculator converts vial size and water volume into concentration and syringe units.

Cosmetic serums and creams at 0.01–0.1% are the form the human skin studies used. The vial is the unformulated copper complex for laboratory work and formulation development.

'Copper peptides' in skincare usually means GHK-Cu, sometimes AHK-Cu; GHK-Cu is the one with the research record.

AHK-Cu is a different copper tripeptide studied mainly for hair; GHK-Cu has the broader skin and wound literature.

GLOW is GHK-Cu blended with BPC-157 and TB-500 for combined skin and repair research.

Cosmetic serums use GHK-Cu at low concentrations in a formulated base for skin application, and that is the form most of the human skin data used. The lyophilised vial is the unformulated copper complex with a batch certificate available on request, intended for laboratory study at concentrations a serum cannot deliver. Our topical-versus-injectable guide walks through the difference.

Published studies measure skin thickness by ultrasound, elasticity by cutometer, wrinkle depth by profilometry, wound area, and follicle diameter in hair models. Our evidence guide summarises the endpoints and the size of the reported changes.

As a cosmetic ingredient at topical concentrations, yes; it is used in registered cosmetics. Injectable or research-grade GHK-Cu is not approved for human use in Australia. Peptide Aus supplies the vial for in-vitro research only.

The 50mg vial suits shorter cell-culture or topical-formulation work. The 100mg vial roughly halves the cost per milligram for longer protocols.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

GHK-Cu is permitted in cosmetics at topical concentrations, but no injectable or research-grade GHK-Cu product is approved for human use in Australia. Peptide Aus supplies the vial for in-vitro laboratory research only.

Directly from Peptide Aus, from Australian stock, in 2 vial sizes from $99.99 (50mg) to $149.99 (100mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.